Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.86)
# 3,721
Out of 4,382 analysts
204
Total ratings
39.3%
Success rate
-1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics | Initiated Coverage: Buy | $12 | $4.42 | +171.49% | 1 | Jun 5, 2026 | |
| CING Cingulate | Maintained: Buy | $10 | $4.50 | +122.47% | 24 | Jun 4, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $10 | $6.37 | +56.99% | 21 | Jun 3, 2026 | |
| PYPD PolyPid | Reiterated: Buy | $9 | $4.50 | +100.00% | 18 | Jun 2, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $38 | $26.71 | +42.27% | 16 | May 29, 2026 | |
| GANX Gain Therapeutics | Reiterated: Buy | $8 | $1.70 | +370.59% | 27 | May 27, 2026 | |
| CRVO CervoMed | Maintained: Buy | $11 → $9 | $2.94 | +206.12% | 18 | May 18, 2026 | |
| LBRX LB Pharmaceuticals | Rated: Buy | $31 → $37 | $28.60 | +29.37% | 5 | May 18, 2026 | |
| LGVN Longeveron | Reiterated: Buy | $2 → $3 | $0.73 | +310.96% | 16 | May 15, 2026 | |
| IMUX Immunic | Rated: Buy | $26 → $19 | $12.77 | +48.79% | 5 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 → $7 | $2.40 | +191.67% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.7501 | +299.95% | 5 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.715 | +39.86% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.56 | n/a | 5 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.2541 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.51 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.89 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $50.43 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $21.07 | n/a | 6 | Oct 24, 2023 |
Coya Therapeutics
Jun 5, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $4.42
Upside: +171.49%
Cingulate
Jun 4, 2026
Maintained: Buy
Price Target: $10
Current: $4.50
Upside: +122.47%
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $10
Current: $6.37
Upside: +56.99%
PolyPid
Jun 2, 2026
Reiterated: Buy
Price Target: $9
Current: $4.50
Upside: +100.00%
Capricor Therapeutics
May 29, 2026
Reiterated: Buy
Price Target: $38
Current: $26.71
Upside: +42.27%
Gain Therapeutics
May 27, 2026
Reiterated: Buy
Price Target: $8
Current: $1.70
Upside: +370.59%
CervoMed
May 18, 2026
Maintained: Buy
Price Target: $11 → $9
Current: $2.94
Upside: +206.12%
LB Pharmaceuticals
May 18, 2026
Rated: Buy
Price Target: $31 → $37
Current: $28.60
Upside: +29.37%
Longeveron
May 15, 2026
Reiterated: Buy
Price Target: $2 → $3
Current: $0.73
Upside: +310.96%
Immunic
May 14, 2026
Rated: Buy
Price Target: $26 → $19
Current: $12.77
Upside: +48.79%
May 14, 2026
Rated: Buy
Price Target: $5 → $7
Current: $2.40
Upside: +191.67%
Apr 27, 2026
Maintained: Buy
Price Target: $3
Current: $0.7501
Upside: +299.95%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.715
Upside: +39.86%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $2.56
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.2541
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $1.51
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $13.89
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $50.43
Upside: n/a
Oct 24, 2023
Maintained: Hold
Price Target: n/a
Current: $21.07
Upside: n/a